Conflicts of interest (COI) & CRO belong to the pharmaceutical Company (CRO b2Ph [Regulatives / Guidelines]

posted by dshah  – India/United Kingdom, 2022-07-08 12:23 (649 d 05:12 ago) – Posting: # 23115
Views: 2,191

Dear Osama!

❝ But let us return to the main topic, should the regulatory authorities refuse the submission and acceptance of BE studies that have been performed in a CRO belonging to the sponsor? are there any references? or are there other opinions other than that?

Unless study trend/result is too much doubtful, regulatory bodies generally does not refuse for submission and acceptance. I believe as a sponsor, the submission of all the studies including failed one is important during such time as it gives impression that sponsor has appropriate formulation which are BE to RLD.


Complete thread:

UA Flag
 Admin contact
22,985 posts in 4,823 threads, 1,653 registered users;
36 visitors (0 registered, 36 guests [including 6 identified bots]).
Forum time: 17:35 CEST (Europe/Vienna)

Complex, statistically improbable things are by their nature
more difficult to explain than
simple, statistically probable things.    Richard Dawkins

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz